Cellular pathology in the COVID-19 era: a European perspective on maintaining quality and safety.


Journal

Journal of clinical pathology
ISSN: 1472-4146
Titre abrégé: J Clin Pathol
Pays: England
ID NLM: 0376601

Informations de publication

Date de publication:
Jan 2021
Historique:
received: 22 05 2020
accepted: 27 05 2020
pubmed: 3 6 2020
medline: 18 12 2020
entrez: 3 6 2020
Statut: ppublish

Résumé

COVID-19 is a zoonotic viral infection that originated in Wuhan, China, in late 2019. WHO classified the resulting pandemic as a 'global health emergency' due to its virulence and propensity to cause acute respiratory distress syndrome. The COVID-19 pandemic has had a major impact on diagnostic laboratories, particularly those handling cell and tissue specimens. This development carries serious implications for laboratory practice in that safety of personnel has to be balanced against high-quality analysis and timely reporting of results. The aim of this article is to present some recommendations for the handling of such specimens in the preanalytical, analytical and postanalytical phases of laboratory testing and analysis in an era of high COVID-19 prevalence, such as that seen, for example, in the UK, Spain, Italy and France.

Identifiants

pubmed: 32482888
pii: jclinpath-2020-206789
doi: 10.1136/jclinpath-2020-206789
pmc: PMC7299655
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

64-66

Informations de copyright

© Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

Déclaration de conflit d'intérêts

Competing interests: None declared.

Références

N Engl J Med. 2020 Feb 20;382(8):727-733
pubmed: 31978945
Int J Antimicrob Agents. 2020 Mar;55(3):105924
pubmed: 32081636
Nat Med. 2020 Jun;26(6):809-810
pubmed: 32382152
J Clin Pathol. 2020 Mar 20;:
pubmed: 32198190
Cancer Cytopathol. 2020 May;128(5):317-320
pubmed: 32259373
J Infect Dis. 2010 Nov 1;202(9):1319-26
pubmed: 20863233
J Clin Pathol. 2020 Apr 20;:
pubmed: 32312717
JAMA. 2020 Apr 28;323(16):1610-1612
pubmed: 32129805
Arch Pathol Lab Med. 2020 Sep 1;144(9):1027-1036
pubmed: 32364793
N Engl J Med. 2020 Mar 26;382(13):1199-1207
pubmed: 31995857

Auteurs

John R Gosney (JR)

Cellular Pathology, Royal Liverpool and Broadgreen Hospitals NHS Trust, Liverpool, UK J.Gosney@liverpoolft.nhs.uk.

Paul Hofman (P)

Pathology, INSERM, Nice, France.

Giancarlo Troncone (G)

Public Health, University of Naplese Federico II, Napoli, Italy.

Fernando Lopez-Rios (F)

Pathology-Targeted therapies laboratory, HM Hospitales, Madrid, Spain.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH